Cocrystal Pharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
COCP Nasdaq 2834 www.cocrystalpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cocrystal Pharma, Inc.

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference - Jun 5th, 2025 6:00 am
Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain - May 29th, 2025 6:00 am
Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference - May 28th, 2025 6:00 am
COCP: Topline Results for High-Dose Cohort from Phase 1 Trial of CDI-988 Expected in 2Q25… - May 27th, 2025 8:08 am
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - May 15th, 2025 6:00 am
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - Apr 24th, 2025 6:00 am
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - Apr 16th, 2025 6:00 am
OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR - Apr 10th, 2025 10:25 am
COCP: Norovirus Challenge Study Planned for 2025… - Apr 1st, 2025 8:15 am
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - Mar 31st, 2025 6:00 am
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Mar 14th, 2025 6:35 am
Life Sciences Investor Forum Agenda Announced for March 13th - Mar 12th, 2025 11:12 am
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 - Mar 6th, 2025 6:00 am
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch - Feb 11th, 2025 1:11 pm
COCP: Phase 2a Trial of CC-42344 Extended… - Jan 8th, 2025 6:05 am
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections - Jan 8th, 2025 6:00 am
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial - Jan 2nd, 2025 4:34 am
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement - Dec 31st, 2024 12:03 pm
Top Midday Decliners - Dec 31st, 2024 11:21 am
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 - Dec 31st, 2024 6:00 am